白细胞介素-1及其受体拮抗剂Anakinra在川崎病中的研究进展  

Research progress of interleukin-1 and its receptor antagonist Anakinra in Kawasaki disease

作　　者：郑远征 侯佳 桂永浩 Zheng Yuanzheng;Hou Jia;Gui Yonghao(Cardiovascular Center,Children′s Hospital of Fudan University,Shanghai 201102,China;Department of Clinical Immunology,Children's Hospital of Fudan University,Shanghai 201102,China)

机构地区：[1]复旦大学附属儿科医院心血管中心,上海201102 [2]复旦大学附属儿科医院临床免疫科,上海201102

出　　处：《中华实用儿科临床杂志》2022年第3期233-237,共5页Chinese Journal of Applied Clinical Pediatrics

摘　　要：川崎病(KD)是一种多发于5岁以下儿童的急性血管炎,易并冠状动脉瘤,是儿童获得性心脏病的主要病因。部分冠状动脉瘤长期存在,远期可能发展为冠状动脉狭窄、血栓形成,甚至心肌梗死,严重威胁儿童健康。KD的病因及发病机制复杂,被公认为由遗传、免疫、炎症、环境等多种因素相互作用所致,白细胞介素-1在KD的发生发展过程中发挥重要作用,现就白细胞介素-1及其受体拮抗剂Anakinra在KD中的研究进展作一综述。Kawasaki disease(KD)is an acute vasculitis that often occurs in children under 5 years of age,leading to coronary artery aneurysms.It is the leading cause of acquired heart disease in children in many countries.Coronary artery stenosis,thrombosis,and even myocardial infarction may occur in the long-term course of KD,which seriously threaten the health of children.The etiology and pathogenesis of KD are complex,and it is recognized that KD is caused by the interaction of multiple factors like the heredity,immunity,inflammation,and environmental factors.Interleukin-1 plays an important role in the occurrence and progression of KD.This study mainly reviews the research progress of interleukin-1 and its receptor antagonist Anakinra in KD.

关 键 词：川崎病 白细胞介素-1 ANAKINRA 

分 类 号：R725.4[医药卫生—儿科]